Rich Pharmaceuticals is committed to developing new therapies to treat life-threatening diseases. Among the most important steps in this process are the clinical trials, where patients offer to receive an experimental new drug and be monitored for its effects.
Results from clinical trials are submitted for review to the U.S. Food and Drug Administration (FDA), which establish safety and efficacy standards for medical products. If a medicine meets these standards, it can be approved and becomes available by prescription.
If you are a patient looking for information about clinical trials, please click here
If you are a medical professional looking for information about clinical trials, please visit the Clinical Trials section of www.RichPharmaceuticals.com for Medical Professionals.
The National Institutes of Health offers up-to-date information on clinical trials for a wide range of diseases and conditions at www.clinicaltrials.gov
Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson’s Disease: Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders
Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials
Rich Pharmaceuticals Announces Institutional Review Board Submission